Biblio
Author Correction: Characterization of an RNA binding protein interactome reveals a context-specific post-transcriptional landscape of MYC-amplified medulloblastoma. Nat Commun. 2023;14(1):136.
Bmi1 regulates human glioblastoma stem cells through activation of differential gene networks in CD133+ brain tumor initiating cells. J Neurooncol. 2019.
Characterization of an RNA binding protein interactome reveals a context-specific post-transcriptional landscape of MYC-amplified medulloblastoma. Nat Commun. 2022;13(1):7506.
Characterization of the minimal residual disease state reveals distinct evolutionary trajectories of human glioblastoma. Cell Rep. 2022;40(13):111420.
Compensatory cross-talk between autophagy and glycolysis regulates senescence and stemness in heterogeneous glioblastoma tumor subpopulations. Acta Neuropathol Commun. 2023;11(1):110.
. Culture and Isolation of Brain Tumor Initiating Cells. Curr Protoc Stem Cell Biol. 2015;34:3.3.1-3.3.13.
. Development of a peptide-based delivery platform for targeting malignant brain tumors. Biomaterials. 2020;252:120105.
Discovery of HDAC6-Selective Inhibitor NN-390 with Efficacy in Group 3 Medulloblastoma. J Med Chem. 2022.
Intratumoral Delivery of Chimeric Antigen Receptor-T Cells Targeting CD133 Effectively Treats Brain Metastases. Clin Cancer Res. 2023.
Metabolism-based targeting of MYC via MPC-SOD2 axis-mediated oxidation promotes cellular differentiation in group 3 medulloblastoma. Nat Commun. 2023;14(1):2502.
Personalizing the treatment of pediatric medulloblastoma: Polo-like kinase PLK1 as a molecular target in high-risk children. Cancer Res. 2013.
Protocol for mapping the metabolome and lipidome of medulloblastoma cells using liquid chromatography-mass spectrometry. STAR Protoc. 2023;4(4):102736.
. The Rational Development of CD133-Targeting Immunotherapies for Glioblastoma. Cell Stem Cell. 2020.
Zr-labeled ImmunoPET targeting the cancer stem cell antigen CD133 using fully-human antibody constructs. EJNMMI Res. 2024;14(1):29.
.